Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes
Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal residual disease.
Medscape Medical News
source https://www.medscape.com/viewarticle/myeloma-adding-daratumumab-maintenance-therapy-improves-mrd-2024a1000hpn?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/myeloma-adding-daratumumab-maintenance-therapy-improves-mrd-2024a1000hpn?src=rss
Comments
Post a Comment